Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 450

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 450
---
 after Commencement, to direct Alpha to purchase up to a specified maximum amount of NLS Common Shares as set forth in the Facility SPA by delivering written notice to Alpha prior to the commencement of trading on any trading day. The purchase price of the NLS Common Shares that the Company elects to sell to Alpha pursuant to the Facility SPA will be 95% of the volume weighted average price of the NLS Common Shares during the applicable purchase date on which the Company has timely delivered written notice to Alpha directing it to purchase NLS Common Shares under the Facility SPA. In connection with the execution of the Facility SPA, the Company agreed to issue a pre -fundedwarrant, or the Pre -FundedWarrant, to purchase $250,000 in NLS Common Shares to Alpha as consideration for its irrevocable commitment to purchase the NLS Common Shares upon the terms and subject to the satisfaction of the conditions set forth in the Facility SPA. Operating Results Operating Expenses Our current operating expenses consist of two components — research and development expenses and general and administrative expenses. Research and Development Expenses, net Our research and development expenses are expensed as incurred and consist primarily of costs of third -partyclinical consultants who conduct clinical and pre -clinicaltrials on our behalf and expenses related to lab supplies, materials and facility costs. Clinical trial costs are a major component of research and development expenses. We accrue and expense clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with 237 clinical research organizations and clinical sites. We determine the actual costs through monitoring patient enrollment and discussions with internal personnel and external service providers as to the progress or stage of completion of trials or services and the agreed -uponfee to be paid for such services. Our research and development expenses have materially increased and will continue to increase in the future as we enter into the Phase 2/3 clinical development stage of our product candidates and initiate a number of new research initiatives that are complementary to our existing and planned research initiatives and thereby recruit additional research and development employees. General and Administrative Expenses General and administrative expenses include personnel costs, expenses for outside professional services, and all other general and administrative expenses. Personnel costs consist of salaries, cash bonuses and benefits. Outside professional services consist of legal fees (including intellectual property and corporate matters), accounting and audit services, IT and other consulting fees. Finance Expense and Income Other expenses include exchange rate differences and financial expenses related to credit card fees. Interest expense relates to interest paid for our financing obligations. Taxation